A BLINDED CONTROLLED STUDY OF ALENDRONATE IN CHRONIC SPINAL CORD INJURY

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。骨密度已知在脊髓损伤人群中受到损害。这项双盲、安慰剂对照、单中心试验将确定一种名为阿仑膦酸钠的药物增加或维持脊髓损伤患者至少18个月后骨密度的能力。参赛者必须在18至60岁之间，必须依靠轮椅行动。参与者将被要求在一年的时间里每天服用钙和维生素D补充剂，每周服用一次阿仑膦酸钠（或安慰剂）。骨密度测量将在入组时使用类似x射线的设备进行，并在6个月和1年后重复。在那一年里，实验室测量将每三个月进行一次，每次测量都需要访问UMMS的GCRC实验室。参与者将获得少量津贴，以支付他们的旅行和其他参与费用

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Bone, Density is known to be compromised in the Spinal Cord Injured Population. This double-blind, placebo-comtrolled, single center trial will ascertain the ability of a medication called alendronate to increase or maintain the bone density of individuals with spinal cord injury who are at least 18 months past their injury. Participants should be between age 18 and 60 and must rely on a wheelchair for mobility. Participants will be asked over a one-year period to take calcium and Vitamin D supplements each day and to take alendronate (or placebo) once each week. Bone density measurements using an x-ray like device will be done at enrollment and repeated at 6 months and one year. Laboratory measurements will be made every three months over that year, and each measurement will require a visit to the GCRC lab at UMMS. Participants will receive a small stipend to cover their travel and other costs of participati